Explore the latest sustainability reporting trends shaping the pharmaceutical industry and understand how leading organizations disclose, measure and manage their ESG performance.
Environmental, social and governance (ESG) reporting has become a strategic priority for pharmaceutical companies as climate, regulatory and stakeholder pressures intensify. Our latest ESG Research white paper analyzes disclosures from North America’s top 100 pharma companies, providing a clear view of reporting behaviors, material topics and emerging challenges. It equips you to strengthen your sustainability strategy and align with evolving global expectations.
In this comprehensive review, we examine how companies are responding to increasing regulatory demands, the rise of impact-driven investors and the growing market expectation for transparency and third-party assurance. These insights help you benchmark your progress, identify gaps and build a more resilient and credible ESG program.
What you’ll find in our white paper
- Key drivers of ESG adoption in pharma
Understand the five forces reshaping ESG reporting in the sector, including regulation, investor expectations, supply chain pressure, consumer demand and talent retention.
- Material topics and performance indicators
Explore the priority ESG topics for pharma companies, from GHG emissions and chemical safety to access to healthcare, occupational health and patient safety and quality.
- Reporting behaviors among the top 100 companies
Learn how many organizations publish stand-alone sustainability reports, align with leading frameworks (CDP, SDGs, TCFD, SASB) and disclose performance targets across environmental and social areas.
- Governance gaps and assurance trends
Gain insight into the significant gaps in ESG governance and third-party assurance, including the fact that only 27 percent of companies disclose independent verification of sustainability data.